Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Biotechnology

Healthcare
$6.30 -4.15%

-$0.41 today

Market cap
$192.17M
Beta
0.78
P/E (TTM)
-1.7
EPS (TTM)
-$5.65
52W Low $5.60High $15.57

Volume 0.17M

Average 0.26M

RNAC Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Cartesian Therapeutics, Inc.NASDAQ: RNAC

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 26.86M shares rose 3.7% year over year, behind the +15.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 3.4% from the prior quarter. Over 3 fiscal years it compounded at +85.8% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.7% toward the trailing-twelve-month pace of +15.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
26.86M+3.4% QoQ
Last fiscal yearDec 2025
25.97M+9.6% YoY
LTMMar 2026
26.32M+15.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.7%——
1 year+9.6%——
3-year CAGR+85.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
25.97M USD
Year-over-year change
+9.6%
4-year CAGR
+69.1%

Weighted Avg Shares (Diluted) vs competitors

How RNAC compares with its peers on the latest reported figures

  • RNAC's LTM Mar 2026 weighted avg shares (diluted) of 26.32M shares is the 6th highest of the 10 companies compared; the peer median is 30.57M shares.
  • Its year-over-year change of +15.6% is the 4th highest of 9, against a peer median of +13.2%.
  • Over three fiscal years its annual growth of +85.8% compares with a peer median of +21.1%.
RNAC Competitors Peer median
Weighted Avg Shares (Diluted) for RNAC and competitors
Company Period LTM YoY 3-year CAGR
IVAInventiva S.A.FY2025186.8M +259.4%+65.2%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026126.35M +0.5%+0.4%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 202645.37M +27.3%+27.5%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 202638.39M +2.6%+14.7%
FENCFennec Pharmaceuticals Inc.LTM Mar 202630.57M +11.5%+2.8%
RNACCartesian Therapeutics, Inc.LTM Mar 202626.32M +15.6%+85.8%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 202621.77M +1.1%+0.7%
NTHINeonc Technologies Holdings, Inc.LTM Mar 202620.19M ——
AVTXAvalo Therapeutics, Inc.LTM Mar 202615.86M +60.9%+599.3%
MDWDMediWound Ltd.LTM Mar 202611.89M +14.9%+31.6%
Peer median (excluding RNAC) 30.57M+13.2%+21.1%

Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue85.08M110.78M26M38.91M2.8M
Cost of Revenue02.04M000
Gross Profit85.08M108.74M26M38.91M2.8M
Gross Margin100.0%98.2%100.0%100.0%100.0%
Research & Development68.74M72.38M71.26M45.11M58.03M
Selling, General & Admin20.94M23.86M40.45M30.13M31.47M
Operating Expenses89.67M94.2M112.42M82.81M89.5M
Depreciation & Amortization1.72M2.04M843K1.15M2.96M
EBITDA(5.16M)39.84M(235.03M)(75.99M)(136.54M)
EBITDA Margin-6.1%36.0%-903.8%-195.3%-4881.5%
Operating Income(4.6M)14.54M(86.42M)(43.9M)(86.71M)
Operating Margin-5.4%13.1%-332.3%-112.8%-3099.9%
Interest Income004.96M7.39M6.58M
Interest Expense2.84M3.03M2.83M00
Other Income / Expenses(5.12M)20.23M(152.29M)(33.24M)(52.79M)
Income Before Tax(9.72M)34.77M(238.71M)(77.14M)(139.5M)
Pre-Tax Margin-11.4%31.4%-918.0%-198.2%-4987.3%
Income Tax Expense15.97M(609K)(19M)287K(9.19M)
Net Income(25.69M)35.38M(219.71M)(77.42M)(130.3M)
Net Margin-30.2%31.9%-844.9%-199.0%-4658.6%
EPS (Basic)(6.74)7.33(49.76)(2.99)(5.02)
EPS (Diluted)(6.60)3.00(49.76)(3.29)(5.02)
Weighted Avg Shares3.18M4.02M5.17M25.91M25.97M
Weighted Avg Shares (Diluted)3.18M4.05M5.17M23.69M25.97M

Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Intrinsic Alpha fair value

Locked

Current Price

$6.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.